COMPARING HIGH INTENSITY WITH LOW INTENSITY STATINS IN ACHIEVING OPTIMAL LDL GOALS AMONG CORONARY ARTERY DISEASE PATIENTS IN SUBURBAN POPULATION IN SOUTH INDIA.

Braunwald E. Unstable angina and non–ST elevation myocardial infarction. Am J Respir Crit Care Med 2012;185(9):924-32.     

Ostadal P. Statins as first-line therapy for acute coronary syndrome? Exp Clin Cardiol 2012;17(4):227-36.

O’Keefe Jr JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. Journal of the American College of Cardiology 2004;43(11):2142-6.              

Catapano AL, Graham I, De Backer G, et al. 2016 ESC/ EAS guidelines for the management of dyslipidaemias. European Heart Journal 2016;37(39):2999-3058.

Hulten E, Jackson JL, Douglas K, et al. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166(17):1814-21.              

Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781-90.                            

Kurabayashi M, Yamazaki T, SUBARU Study Group. Superior benefit of aggressive lipid-lowering therapy for high-risk patients using statins: the SUBARU study – more hypercholesterolemic patients achieve Japan atherosclerosis society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. Journal of Atherosclerosis and Trombosis 2008;15(6):314-23.      

Park JS, Kim YJ, Choi JY, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med 2010;25(1):27-35.         

Lee CW, Kang SJ, Ahn JM, et al. Comparison of effects of Atorvastatin (20 mg) versus Rosuvastatin(10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP Trial). Am J Cardiol 2012;109(12):1700-4.            

Pitt B, Loscalzo J, Monyak J, et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR Study). Am J Cardiol 2012;109(9):1239-46.            

Khurana S, Gupta S, Bhalla H, et al. Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. J Pharmacol Pharmacother 2015;6(3):130-5.              

Thapa R, Rai P, Mahara L, et al. A comparative study of atorvastatin and rosuvastatin in dyslipidemia. Int J Basic & Clin Pharmacol 2017;6(11):2551-5.  

Leibovitz E, Harats D, Gavish D. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study. Isr Med Assoc J 2002;4(6):407-10.                    

Yood MU, McCarthy BD, Kempf J, et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J 2006;152(4):777-84.           

LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35.    

Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504.        

Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295(13):1556-65.               

Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291(9):1071-80.              

Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care 2006;12(Suppl 15):S405-S11.